BridgeBio secures $1.25bn for genetic therapy development
Pharmaceutical Technology
JANUARY 19, 2024
BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
JANUARY 19, 2024
BridgeBio Pharma has secured strategic financing of $1.25bn from Blue Owl Capital and CPP Investments for genetic therapies.
Pharmaceutical Technology
APRIL 22, 2024
Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Worldwide Clinical Trials
JANUARY 24, 2024
Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.
Pharmaceutical Technology
APRIL 22, 2024
Enhance immunoglobulin diversity with AbCellera's patented method for isolating B cells from genetically modified mice. Discover a broader repertoire of antibodies with a recently granted patent.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 18, 2024
Indian healthcare industry is of the view that emergence of genetic diagnostics will be a paradigm shift towards personalized medicine. Through the ever-evolving landscape of healthcare, the role of genetic diagnostics offers personalized insights and proactive solutions for disease management and prevention.
Pharmaceutical Technology
JULY 18, 2023
Scribe Therapeutics and Sanofi have expanded partnership to progress the development of in vivo genetic therapies to treat genomic diseases.
Pharmaceutical Technology
SEPTEMBER 19, 2023
Pelican Technology has combined business with Primordial Genetics under a deal to create a private biotechnology company Primrose Bio.
Pharmaceutical Technology
MARCH 28, 2024
Discover how Synlogic Inc's patented genetically programmed microorganisms can modulate and treat diseases. Learn about the innovative method for producing pharmaceutical compositions using non-pathogenic bacteria to metabolize phenylalanine. Explore the potential applications in gut microbiome and tumor environments.
Pharmaceutical Technology
SEPTEMBER 15, 2023
Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.
Pharmaceutical Technology
MARCH 29, 2024
Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.
Pharmaceutical Technology
MARCH 1, 2024
1910 Genetics has entered an agreement with Microsoft, aiming to revitalise pharmaceutical research and development (R&D) productivity.
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 13, 2023
Now an international team of researchers has discovered a new genetic variant in people of African ancestries that appears to restrict HIV replication after an infection sets in. A tiny fraction of people are naturally resistant to HIV infections, and scientists want to understand why.
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.
Bio Pharma Dive
MARCH 14, 2022
Lynparza is the first drug targeting BRCA mutations to be approved for use in early breast cancer, a decision that could lead to more genetic testing.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 14, 2023
Indian healthcare looks at pharmacogenomics, the study of influence of genetic factors on drug response, in patient care as comprehensive genetic tests gain ground.
Pharmaceutical Technology
NOVEMBER 8, 2022
Fulgent Genetics has acquired clinical-stage therapeutics development firm Fulgent Pharma for a total deal price of nearly $100m. According to the deal, the purchase price, contingent on adjustments, has to be paid by Fulgent Genetics as a combination of cash on hand and its shares of common stock.
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.
Pharmaceutical Technology
MARCH 24, 2023
Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. Moderna’s biological and technical expertise will be combined with core technologies of the non-viral genetic medicine platform from Generation Bio.
Pharmaceutical Technology
FEBRUARY 13, 2023
SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. This collaboration aims to use the global SOPHiA DDM platform, a cloud-native platform of SOPHiA GENETICS, and multimodal algorithmic capabilities for AstraZeneca’s oncology portfolio.
Bio Pharma Dive
FEBRUARY 11, 2021
Ensoma Therapeutics debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body.
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 21, 2022
Scientists have found an extremely subtle twist in the genetics of aging cells, one that seems to make them increasingly less functional as time goes on.
BioSpace
DECEMBER 12, 2023
Ahead of an expected surge in regulatory filings, the FDA is establishing the Genetic Metabolic Diseases Advisory Committee to provide advice on treatments for these complex and challenging conditions.
Pharmaceutical Technology
JUNE 4, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. However, not all innovations are equal and nor do they follow a constant upward trend.
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models.
Pharmaceutical Technology
MAY 25, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The first patients will have their genetic makeup sequenced in Spring 2024 and this data will be shared in 2025.
Worldwide Clinical Trials
FEBRUARY 6, 2023
When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. Read the full article!
pharmaphorum
DECEMBER 11, 2023
Predictive genetic testing offers the greatest promise and ethical challenge of our time Mike.Hammerton Mon, 11/12/2023 - 11:00 Bookmark this
Pharmaceutical Technology
DECEMBER 20, 2023
LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).
Medical Xpress
MAY 8, 2023
An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.
Eye on FDA
MARCH 7, 2024
Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC). The vote of any committee is advisory in nature, and not binding on the agency’s final decision.
Pharma Times
SEPTEMBER 21, 2022
A new genetically engineered virus has delivered a one-two punch in initial phase 1 trial
XTalks
MARCH 28, 2024
Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein.
Medical Xpress
MAY 1, 2023
The condition's origins and progression are not well understood, and it has been unclear if genetic mutations may contribute to TLE. Patients with this form of epilepsy may require neurosurgery to provide relief from seizures.
Drug Discovery World
MARCH 18, 2024
Landmark genetic research could allow doctors to accurately predict whether a patient is at risk of developing common diseases, decades before any symptoms would become evident. The post $8 million awarded to landmark genetic research project appeared first on Drug Discovery World (DDW).
STAT News
DECEMBER 10, 2022
NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Continue to STAT+ to read the full story…
Medical Xpress
MARCH 21, 2023
The cellular glitches underlying a rare genetic disorder called activated PI3K Delta syndrome 2 (APDS2) have been identified by researchers at the Garvan Institute of Medical Research. The disorder is caused by genetic variations that disrupt immune cell signaling through a protein called PI3K.
Medical Xpress
MAY 3, 2023
Genetic testing for hereditary cancers, such as breast, colon, pancreatic, and ovarian cancer, helps at-risk individuals understand their familial risk for these diseases and make informed decisions about next steps in care.
Drug Discovery World
APRIL 9, 2024
The scientists genetically modified dendritic cells to produce CXCL9 and CXCL10 and then injected these directly into the tumours in mouse models of NSCLC. Diana Spencer, Senior Digital Content Editor, DDW The post Genetically engineered dendritic cells enhance lung cancer therapy appeared first on Drug Discovery World (DDW).
Outsourcing Pharma
JANUARY 23, 2024
Sano Genetics says it is developing software that will enable âthe precision medicine revolutionâ and has raised $11.4 million in new funding.
pharmaphorum
SEPTEMBER 20, 2023
DeepMind applies its AI expertise to genetic diseases Phil.Taylor Wed, 20/09/2023 - 07:55 Bookmark this
BioPharma Reporter
JANUARY 25, 2024
Genetic Design and Manufacturing Corporation (GDMC) has bagged $21 million in Series A funding to accelerate its next-gen advanced genetic therapies.
Scienmag
APRIL 14, 2022
In a Policy Forum, Anna Lewis and colleagues argue that, for researchers and others who want to invoke genetic ancestry, there is a scientific and ethical imperative to move away from continental ancestry categories and to instead embrace a view of genetic ancestry that reflects continuous variation and historical depth.
pharmaphorum
JANUARY 24, 2023
Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates. The logical extension to this kind of approach is treating individual patients, with their individual genetic makeup.
Medical Xpress
MAY 8, 2023
Scientists at the National Institutes of Health have identified new genetic risk factors for two types of non-Alzheimer's dementia. These findings were published in Cell Genomics and detail how researchers identified large-scale DNA changes, known as structural variants, by analyzing thousands of DNA samples.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content